A three-dimensional in vitro model of erythropoiesis recapitulates erythroid failure in myelodysplastic syndromes.
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
19
01
2019
accepted:
20
05
2019
revised:
13
05
2019
pubmed:
4
8
2019
medline:
2
7
2020
entrez:
4
8
2019
Statut:
ppublish
Résumé
Established cell culture systems have failed to accurately recapitulate key features of terminal erythroid maturation, hampering our ability to in vitro model and treat diseases with impaired erythropoiesis such as myelodysplastic syndromes with ring sideroblasts (MDS-RS). We developed an efficient and robust three-dimensional (3D) scaffold culture model supporting terminal erythroid differentiation from both mononuclear (MNC) or CD34
Identifiants
pubmed: 31375745
doi: 10.1038/s41375-019-0532-7
pii: 10.1038/s41375-019-0532-7
pmc: PMC7214248
doi:
Substances chimiques
Antigens, CD34
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
271-282Références
Hattangadi SM, Wong P, Zhang L, Flygare J, Lodish HF. From stem cell to red cell: regulation of erythropoiesis at multiple levels by multiple proteins, RNAs, and chromatin modifications. Blood. 2011;118:6258–68.
pubmed: 21998215
pmcid: 3236116
Palis J. Primitive and definitive erythropoiesis in mammals. Front Physiol. 2014;5:1–9.
An X, Mohandas N. Erythroblastic islands, terminal erythroid differentiation and reticulocyte maturation. Int J Hematol. 2011;93:139–43.
pubmed: 21293952
Korolnek T, Hamza I. Macrophages and iron trafficking at the birth and death of red cells. Blood. 2015;125:2893–7.
pubmed: 25778532
pmcid: 4424413
Bessis M. Erythroblastic island, functional unity of bone marrow. Rev Hematol. 1958;13:8–11.
pubmed: 13555228
Platzbecker U, Hofbauerb LC, Ehningera G, Höliga K. The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes. Leuk Res. 2012;36:525–36.
pubmed: 22300879
Malcovati L, Papaemmanuil E, Bowen DT, Boultwood J, Della Porta MG, Pascutto C, et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood. 2011;118:6239–46.
pubmed: 21998214
pmcid: 3236114
Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. New Engl J Med. 2011;365:1384–95.
pubmed: 21995386
Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478:64–9.
Arber A, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.
Conte S, Katayama S, Vesterlund L, Karimi M, Dimitriou M, Jansson M, et al. Aberrant splicing of genes involved in haemoglobin synthesis and impaired terminal erythroid maturation in SF3B1 mutated refractory anaemia with ring sideroblasts. Br J Haematol. 2015;171:478–90.
pubmed: 26255870
pmcid: 4832260
Mufti GJ, Bennett JM, Goasguen J, Bain BJ, Baumann I, Brunning R, et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica. 2008;93:1712–7.
pubmed: 18838480
Patnaik MM, Hanson CA, Sulai NH, Hodnefield JM, Knudson RA, Ketterling RP, et al. Prognostic irrelevance of ring sideroblast percentage in World Health Organization–defined myelodysplastic syndromes without excess blasts. Blood. 2012;119:5674–7.
pubmed: 22538853
Cazzola M, Invernizzi R, Bergamaschi G, Levi S, Corsi B, Travaglino E, et al. Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. Blood. 2003;101:1996–2000.
pubmed: 12406866
Tehranchi R, Fadeel B, Forsblom AM, Christensson B, Samuelsson J, Zhivotovsky B, et al. Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood. 2003;101:1080–6.
pubmed: 12393561
Tehranchi R, Invernizzi R, Grandien A, Zhivotovsky B, Fadeel B, Forsblom AM, et al. Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes. Blood. 2005;106:247–53.
pubmed: 15755901
Mortera-Blanco T, Dimitriou M, Woll P, Karimi M, Elvarsdottir E, Conte S, et al. SF3B1-initiating mutations in MDS with rings sideroblasts target lymphomyeloid hematopoietic stem cells. Blood. 2017;130:881–90.
pubmed: 28634182
pmcid: 5572789
Song Y, Rongvaux A, Taylor A, Jiang T, Tebaldi T, Balasubramanian K, et al. A highly efficient and faithful MDS patient-derived xenotransplantation model for pre-clinical studies. Nat Commun. 2019;10:366.
pubmed: 30664659
pmcid: 6341122
Thanopoulou E, Cashman J, Kakagianne T, Eaves A, Zoumbos N, Eaves C. Engraftment of NOD/SCID-2 microglobulin null mice with multilineage neoplastic cells from patients with myelodysplastic syndrome. Blood. 2004;103:4285–93.
pubmed: 14962905
Nilsson L, Astrand-Grundström I, Anderson K, Arvidsson I, Hokland P, Bryder D, et al. Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. Blood. 2002;100:259–67.
pubmed: 12070035
Mupo A, Seiler M, Sathiaseelan V, Pance A, Yang Y, Agrawal A, et al. Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts. Leukemia. 2017;31:720–7.
pubmed: 27604819
Obeng EA, Chappell RJ, Seiler M, Chen MC, Campagna DR, Schmidt PJ, et al. Physiologic expression of Sf3b1K700E causes impaired erythropoiesis, aberrant splicing, and sensitivity to therapeutic spliceosome modulation. Cancer Cell. 2016;30:404–17.
pubmed: 27622333
pmcid: 5023069
Blanco TM, Mantalaris A, Bismarck A, Panoskaltsis N. The development of a three-dimensional scaffold for ex vivo biomimicry of human acute myeloid leukaemia. Biomaterials. 2010;31:2243–51.
pubmed: 20015543
Mortera-Blanco T, Mantalaris A, Bismarck A, Aqel N, Panoskaltsis N. Long-term cytokine-free expansion of cord blood mononuclear cells in three-dimensional scaffolds. Biomaterials. 2011;32:9263–70.
pubmed: 21908041
Claessens Y-E, Bouscary D, Dupont M-J, Picard F, Melle J, Gisselbrecht S, et al. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood. 2002;99:1594–601.
pubmed: 11861273
Freyssinier JM, Lecoq-Lafon C, Amsellem S, Picard F, Ducrocq R, Mayeux P, et al. Purification, amplification and characterization of a population of human erythroid progenitors. Br J Haematol. 1999;106:912–22.
pubmed: 10519992
Nikpour M, Scharenberg C, Liu A, Conte S, Karimi M, Mortera-Blanco T, et al. The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts. Leukemia. 2013;27:889–96.
pubmed: 23070040
Byrnes C, Terry Lee Y, Meier ER, Rabel A, Sacks DB, Miller JL. Iron dose-dependent differentiation and enucleation of human erythroblasts in serum-free medium. J Tissue Eng Regen Med. 2013;10:E84–89.
pubmed: 23606586
pmcid: 3883763
Ponka P, Sheftel A. Erythroid iron metabolism. In: Iron physiology and pathophysiology in humans, nutrition and health. Human Press; 2012. p. 191–209.
Safinia L, Datanb N, Höhseb M, Mantalarisa A, Bismarcka A. Towards a methodology for the effective surface modificationof porous polymer scaffolds. Biomaterials. 2005;26:7537–47.
pubmed: 16009420
Malcovati L, Karimi M, Papaemmanuil E, Ambaglio I, Jadersten M, Jansson M, et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood. 2015;126:233–41.
pubmed: 25957392
pmcid: 4528082
Fajtova M, Kovarikova A, Peter Svec P, Kankuri E, Sedlak J. Immunophenotypic profi le of nucleated erythroid progenitors during maturation in regenerating bone marrow. Leuk Lymphoma. 2013;54:2523–30.
pubmed: 23452116
Ji P, Jayapal SR, Lodish HF. Enucleation of cultured mouse fetal erythroblasts requires Rac GTPases and mDia2. Nat Cell Biol. 2008;10:314–21.
pubmed: 18264091
Cory AH, Owen TC, Barltrop JA, Cory JG. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun. 1991;3:207–12.
pubmed: 1867954
Buesche G, Teoman H, Giagounidis A, Göhring G, Schlegelberger B, Ganser A, et al. Impaired formation of erythroblastic islands is associated with erythroid failure and poor prognosis in a significant proportion of patients with myelodysplastic syndromes. Haematologica. 2016;101:e177–81.
pubmed: 26944473
pmcid: 5004355
Han Y, Zhang G, Wang H, Fu R, Xing L, Li L, et al. GDF11 is increased in patients with myelodysplastic syndrome. Int J Clin Exp Pathol. 2016;9:6031–8.
Zhou L, McMahon C, Bhagat T, Alencar C, Yu Y, Fazzari M, et al. Reduced SMAD7 leads to overactivation of TGF-b signaling in MDS that can be reversed by a specific inhibitor of TGF-b receptor I kinase. Cancer Res. 2011;71:955–63.
pubmed: 21189329
Zhou L, Nguyen AN, Sohal D, Ma JY, Pahanish P, Krishna Gundabolu K, et al. Inhibition of the TGF- receptor I kinase promotes hematopoiesis in MDS. Blood. 2008;112:3434–43.
pubmed: 18474728
pmcid: 2569182
Zermati Y, Fichelson S, Valensi F, Freyssinier JM, Rouyer-Fessard P, Cramer E, et al. Transforming growth factor inhibits erythropoiesis by blocking proliferation and accelerating differentiation of erythroid progenitors. Exp Hematol. 2000;28:885–94.
pubmed: 10989189
Krystal G, Lain V, Dragowska W, Takahashi C, Appel J, Gontier A, et al. Transforming growth factor β1 is an inducer of erythroid differentiation. J Exp Med. 1994;180:851–60.
pubmed: 7520475
Hino M, Tojo A, Miyazono K, Urabe A, Takaku F. Effects of type β transforming growth factors on haematopoietic progenitor cells. Br J Haematol. 1988;70:143–7.
pubmed: 3191027
Suragani RN, Cadena SM, Cawley SM, Sako D, Mitchell D, Li R, et al. Transforming growth factor-beta superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014;20:408–14.
pubmed: 24658078
Wang C, Udupa WK, Lipschitz DA. Evidence suggesting a stimulatory role for interleukin-1 0 in erythropoiesis in vitro. J Cell Physiol. 1996;166:305–10.
pubmed: 8591990
Johnson CS, Keckler DJ, Topper MI, Braunschweiger PG, Furmansk P. In vivo hematopoietic effects of recombinant interleukin-la in mice: stimulation of granulocytic, monocytic, megakaryocytic, and early erythroid progenitors, suppression of late-stage erythropoiesis, and reversal of erythroid suppression with erythropoietin. Blood. 1989;73:678–83.
pubmed: 2783864
Rivella S. Ineffective erythropoiesis and thalassemias. Curr Opin Hematol. 2009;16:187–94.
pubmed: 19318943
pmcid: 3703923
Dussiot M, Maciel TT, Fricot A, Chartier C, Negre O, Veiga J, et al. An activin receptor IIA ligand trap corrects ineffective erythropoiesis in beta-thalassemia. Nat Med. 2014;20:398–407.
pubmed: 24658077
Medyouf H, Mossner M, Jann JC, Nolte F, Raffel S, Herrmann C, et al. Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. Cell Stem Cell. 2014;14:824–37.
pubmed: 24704494
Lazar-Karsten P, Dorn I, Meyer G, Lindner U, Driller B, Schlenke P. The influence of extracellular matrix proteins and mesenchymal stem cells on erythropoietic cell maturation. Vox Sang. 2011;101:65–76.
pubmed: 21175667
Iancu-Rubina C, Mosoyana G, Wanga J, Krausb T, Sungc V, Hoffmana R. Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap. Exp Hematol. 2013;41:155–66.
Griffith LG, Swartz MA. Capturing complex 3D tissue physiology in vitro. Nat Rev Mol Cell Biol. 2006;7:211–24.
pubmed: 16496023
Severn CE, Macedo H, Eagle MJ, Rooney P, Mantalaris A, Toye AM. Polyurethane scaffolds seeded with CD34+ cells maintain early stem cells whilst also facilitating prolonged egress of haematopoietic progenitors. Sci Rep. 2016;6:1–12.